Thursday, 30 June 2022

Lupin launches authorised generic version of Antara in US

03 November 2021 | News

Fenofibrate capsules are indicated as adjunctive therapy to diet to reduce elevated low-density lipoprotein cholesterol

Image Credit: Shutterstock

Image Credit: Shutterstock

Lupin announced the launch of the authorised generic version of Antara (Fenofibrate) Capsules, 30 mg and 90 mg, of Lupin Atlantis Holdings, SA Corporation, a wholly-owned subsidiary of Lupin.

Fenofibrate capsules are indicated as adjunctive therapy to diet to reduce elevated low-density lipoprotein cholesterol (LDL-C), total cholesterol (total-c), Triglycerides (TG) and apolipoprotein B (Apo B), and to increase high-density lipoprotein cholesterol (HDL-C) in adult patients with primary hypercholesterolemia.

Fenofibrate Capsules (RLD: Antara4 Capsules) had estimated annual sales of $7 million in the US (IQVIA MAT September 2021).

 

Comments

× Your session has been expired. Please click here to Sign-in or Sign-up
   New User? Create Account